November 18, 2023

Yesterday, on the sidelines of the VI Kazakhstan Global Investment Roundtable, with the participation of the Prime Minister of the Republic of Kazakhstan Alikhan Smailov, a long-term agreement was signed between the Pfizer Single Distributor SK-Pharmacia and the international biopharmaceutical company .
As part of this agreement,  Pfizer, the American pharmaceutical giant  undertakes to organize the contract production of an innovative vaccine in the country and supply the 20-valent pneumococcal conjugate vaccine to Kazakhstan for 10 years.

The vaccine will be purchased by the Single Distributor, which since 2009 has been organizing the centralized purchase of medicines purchased from the state budget for further transfer to healthcare organizations. Patrick van der Loo, the regional President of the company in the Middle East, Russia and Africa (MERA) region, arrived in Kazakhstan to sign the document.

Kazakhstan has become the first country in the Eurasian region and Central Asian countries where Pfizer plans to establish contract production of an innovative vaccine.

As part of the execution of the order of the Head of State to attract global players in the pharmaceutical industry to the Kazakhstan market, large-scale work has been carried out to prepare for the organization of contract manufacturing based on local manufacturers, as well as the exchange of experience and technology transfer.

In February of this year, a Roadmap for the implementation of the project was signed between Pfizer, the Ministry of Health of the Republic of Kazakhstan and the Ministry of Foreign Affairs of the Republic of Kazakhstan.

Vaccination against pneumococcal infection has been included in the National Calendar of Preventive Vaccinations of Kazakhstan since 2010. Before the start of mass immunization, pneumonia was one of the leading causes of death in children under 1 year of age in the country. The introduction of vaccination into the National Calendar made it possible to reduce the mortality rate among children in this age group by more than 2.5 times.

The second major event was the signing of a long-term agreement for the supply of original patented medicines between the Swiss company F. Hoffmann-La Roche Ltd, the Single Distributor SK-Pharmacia LLP, Nobel Almaty Pharmaceutical Factory JSC (Nobel AFF) and the Kazakhstan Research Institute of Oncology and radiology (KazNIIOiR) on the basis of the Localization Agreement signed on December 1, 2022 between the Ministry of Health of the Republic of Kazakhstan and Roche.

The official signing of the Long-Term Agreement took place within the framework of the key investment event in the country – the Kazakhstan Round Table on Global Investment, chaired by the Prime Minister of the Republic of Kazakhstan A. Smailov.

As part of the Localization Agreement, Roche has committed to ensure the transfer of advanced technology and know-how for the local production of three biotechnological medicines on a contract manufacturing basis and the subsequent supply of original patented medicines by a local partner under a Long-Term Agreement. This important step will help reduce the cost and increase the availability of high-quality medicines. Cooperation between KazNIIOiR and Roche will ensure the availability of innovative anticancer drugs for cancer patients.

Cooperation with the global pharmaceutical giant Roche will bring to Kazakhstan not only new technologies, but its entire philosophy of health. Health philosophy is a comprehensive approach to understanding and achieving health. Today we see the galloping growth of technologies that are changing the practice of healthcare delivery, the healthcare system and the world as a whole. Today, in addition to localizing production, the company intends to continue cooperation and conduct a number of joint projects in the country.

For example, at the School of Medicine of Nazarbayev University, an innovative training center for laboratory diagnostics was created within the framework of the Localization Agreement signed between the Ministry of Health of the Republic of Kazakhstan and Roche. The company plans to supply this training center with reagents free of charge. The educational and innovative program at the training center is aimed at comprehensive advanced training and training of specialists from all over Kazakhstan.

Thus, Roche provides assistance in the implementation of new diagnostic methods for research projects. This helps strengthen Kazakhstan’s laboratory infrastructure and ensure its compliance with international standards. In addition, it will give impetus to the development of medical and pharmaceutical clusters in the country, the creation of which was initiated by the Single Distributor.

In addition, Roche, together with KazNIIOiR, conducts screenings, which allows for early detection of cancer.

The signing of a long-term agreement marks an important step in the development